Medilex consulting - Company finances
|
EUR
|
2021
From: 2021-03-25
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|
|
Financial data
|
|||||
| Sales revenue | - | 5,953 | 13,282 | 12,330 | 17,912 |
| Profit before tax | 0 | 4,943 | 7,723 | 11,579 | -11,451 |
| Net profit | 0 | 4,193 | 6,565 | 9,842 | -11,451 |
| Equity | 0 | 9,885 | 16,358 | 26,117 | 14,666 |
| Liabilities | - | 4,698 | 4,689 | 5,184 | -524 |
| Non-current assets | 0 | 9,851 | 15,150 | 23,666 | 9,173 |
| Current assets | 0 | 4,732 | 5,897 | 7,635 | 4,969 |
| Total assets | 0 | 14,583 | 21,047 | 31,301 | 14,142 |
|
Taxes paid
|
|||||
| STI taxes | - | - | 741 | 1,158 | 5,936 |
|
Financial indicators
|
|||||
| Revenue change y/y | - | - | +123.1% | -7.2% | +45.3% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | - | 28.8% | 31.2% | 31.4% | -81.0% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | 42.4% | 40.1% | 37.7% | -78.1% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | - | 70.4% | 49.4% | 79.8% | -63.9% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | 83.0% | 58.1% | 93.9% | -63.9% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | 0.5 | 0.3 | 0.2 | - |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Medilex consulting - Social security debts
The company had no debts to Sodra
Medilex consulting - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-07-03 | 2025-07-20 | 531.3 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Medilex consulting, MB (code 305695217) is a Lithuanian Small partnership engaged in Legal activities. In the latest financial year, 2025, the company generated revenue of €17.9K, up 45.3% year on year and 34.9% over two years. This followed revenue of €13.3K in 2023 and €12.3K in 2024, showing a modest dip before a stronger recovery. Profitability weakened sharply in 2025: net profit turned to a loss of €11.5K from a profit of €9.8K in 2024 and €6.6K in 2023, while the net margin moved to -63.9% from 79.8% and 49.4% in the prior two years. Balance sheet size also contracted in 2025, with total assets of €14.1K versus €31.3K in 2024, equity of €14.7K, and liabilities reported at -€524. Key ratios show a weak return profile, with ROE at -78.1%, ROA at -81.0%, debt-to-equity at -0.04, and asset turnover at 1.27x. The company remained revenue-generative, but earnings and balance sheet strength deteriorated in 2025.